LoginRegister

    Dr Reddys launches generic version of Tobi in US market

    Farhat NasimWritten by Farhat Nasim   |  

    The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).


    Hyderabad: Dr Reddy's Laboratories Ltd. (Dr Reddys), along with its subsidiaries together referred to as "Dr Reddy's") recently announced the launch of Tobramycin Inhalation Solution, USP in the United States' market.


    The product is a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA). Tobi is indicated for the management of cystic fibrosis


    Also Read: Dr Reddys unveils generic version of Vitamin K1 injection in US


    The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.


    Dr Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.


    Tobi is a trademark of Mylan.



    Based in Hyderabad, Dr Reddys was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.

    Also Read: Dr Reddys gets two USFDA observations for Vizag plants

    Cystic FibrosisDr Reddy'sDr Reddy's LaboratoriesDr Reddy's Labsgeneric drugMylanpharmapharma newspharma news indiaTOBITobi inhalation solutionTobramycinTobramycin inhalation solutionUSUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X